slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 62,431-62,460
Pages 2,605
Rows per page 30
Component
62,431-62,460 of 78,138
06
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
07
The chart uses a conceptual scatter plot to contrast current SOC with a future target state, emphasizing the need for higher efficacy and better convenience.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
09
The chart illustrates the correlation between Cyno and Human half-life, showing YTE mAbs (Spyre's approach) outperforming WT mAbs.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
10
The slide uses a visual metaphor of two antibodies merging into a single complex to represent combination therapy.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
11
The Venn diagram shows the intersection of genetic targets (TL1A, IL-23, a4b7). The bar chart compares 'All-comers' vs 'CDx+' (companion diagnostic positive) patient groups for two drugs (PRA023 and RVT-3101).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Solution & ApproachLoop · Golden Circle1 hit
15
The chart uses a vertical axis to categorize drugs by mechanism of action (α4β7, IL-23s, TNFαs, S1P1s, JAKs) and a horizontal axis for efficacy (Pbo-adjusted clinical remission %).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
20
The chart shows a biphasic exponential decay curve for three datasets.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
24
Data from GEMINI 1 study; compares Q8W and Q4W dosing regimens.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
26
The slide uses a dual-axis approach: a bar chart for valuation benchmarks and a timeline for clinical milestones.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
27
The slide uses a visual pipeline format to track progress from Discovery to Clinical stages for specific drug candidates.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
35
The slide uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
36
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
11
The chart uses a highlighted bar for the most recent quarter (2023-Q1) to emphasize the record-high performance.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
20
The chart is a forest plot showing LS Mean differences with 95% confidence intervals for various OHQ questionnaire scores.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
28
The chart shows a significant reduction in operating expenses from 2020 to 2023 guidance.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
05
The slide uses a waterfall bridge to reconcile equity adjustments between two entities.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
09
The chart bridges Credit Suisse equity to pro forma negative goodwill via transaction adjustments.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
06
2020 data is omitted due to COVID-19 pandemic.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
The slide explains the dual-class structure and how it relates to financial reporting and economic interest.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
18
The chart includes a trend line showing a 3-4% CAGR over the period.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
05
Data source: China National Bureau of Statistics (CNBS).Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
10
The chart highlights a strategic reduction in offline retail footprint throughout 2022.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations 1 hit
13
The slide explains the drivers behind the reduction in G&A and S&M expenses, specifically citing share-based compensation reversals and store closures.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Visualization1 hit
15
The chart displays quarterly operating cashflow as bars and the total cash balance as oval-enclosed numbers above the bars.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Visualization1 hit